PLYX.US Polaryx Therapeutics, Inc. Common Stock
- Market cap
- USD 75.7M
- P/E
- -
- P/B
- 10.94x
- ROE
- -127.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PLYX.US undervalued?
Graham numberThe Graham number of Polaryx Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Polaryx Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Polaryx Therapeutics, Inc. Common Stock yet.
Polaryx Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, …
Full company profilePolaryx Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Polaryx Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.78M | -4.35M | -7.82M | -8.89M |
| EBITDA | -3.78M | -30.4M | -8.99M | -9.67M |
| Net Income | -3.78M | -30.4M | -8.99M | -9.67M |
| EPS | -0.02 | -0.16 | -0.19 | -0.19 |
| Balance Sheet | ||||
| Total Assets | 2.32M | 5.00M | 5.17M | 8.61M |
| Total Liabilities | 1.04M | 289K | 605K | 999K |
| Shareholders' Equity | 1.28M | 4.71M | 4.57M | 7.61M |
| Cash & Short-term Investments | 2.00K | 4.62M | 5.14M | 8.44M |
| Total Debt | 128K | - | - | - |
| Cash Flow | ||||
| Operating Cash Flow | -173K | -2.57M | -3.94M | -8.71M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -173K | -2.57M | -3.94M | -8.71M |
| Ratios | ||||
| ROE | -295.9% | -644.2% | -196.8% | -127.0% |
| ROA | -163.2% | -607.0% | -173.8% | -112.3% |
| Debt to Equity | 0.10x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Polaryx Therapeutics, Inc. Common Stock dividends
Polaryx Therapeutics, Inc. Common Stock has not paid dividends in the last 3 fiscal years.
Who owns Polaryx Therapeutics, Inc. Common Stock
- Insiders 69.92%
- Institutions 4.16%
- Public & others 25.92%
- Shares outstanding 47.3M
- Free float 7.17M
Top funds holding PLYX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.47M | 2.95% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 44.9K | 0.09% | -31.12% | Sep 2026 |
| Fidelity Total Market Index | 26.5K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 26.0K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 21.9K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 19.6K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 19.0K | 0.04% | -33.53% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 6.32K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding PLYX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.66M | 3.33% | -0.03% | Jun 2026 |
| Geode Capital Management, LLC | 171K | 0.34% | +0.19% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 105K | 0.21% | +0.49% | Jun 2026 |
| HRT FINANCIAL LLC | 82.1K | 0.16% | 0.00% | Jun 2026 |
| State Street Corp | 58.1K | 0.12% | 0.00% | Jun 2026 |
| BlackRock Inc | 41.0K | 0.08% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 31.4K | 0.06% | 0.00% | Jun 2026 |
| Northern Trust Corp | 28.0K | 0.06% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 7.73K | 0.02% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 6.32K | 0.01% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.00K | 0.01% | +68.56% | Jun 2026 |
| UBS Group AG | 1.28K | 0.00% | -90.48% | Jun 2026 |
| Fortitude Family Office LLC | 189.00 | 0.00% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Millennium Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Squarepoint Ops LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
Polaryx Therapeutics, Inc. Common Stock company profile
- Company name
- Polaryx Therapeutics, Inc. Common Stock
- Ticker
- PLYX.US
- Exchange
- USA Stocks
- Listed since
- Feb 2, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- South Tower, Paramus, NJ, United States, 07652
- Phone
- 201 940 7236
- Website
- polaryx.com
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Polaryx Therapeutics, Inc. Common Stock management
6- Mr. Alex Yang J.D., L.L.M.CEO & Chair of Board · born 1970
- Mr. G. Michael Landis CPACFO & Director · born 1966
- Mr. Andrew John OChief Investment Officer · born 1973
- Dr. Shrijay Vijayan M.B.A., Ph.D.Chief Scientific & Business Development Officer · born 1968
- Mr. Wuxin Zhu P.M.P., Ph.D.Chief Chemistry, Manufacturing & Controls Officer · born 1980
- Dr. Ralph William Charlton III, M.D.Chief Medical Officer · born 1970